Targeted Oncology
Targeted Oncology
Targeted Oncology


Targeted Oncology | Dialogues in Diagnostics
Targeted Oncology | Differential Diagnosis
Targeted Oncology | Case-Base Peer-Perspective

Top Medical News Today

Ceritinib Granted Priority Review by the FDA in Frontline ALK+ NSCLC
Ceritinib has been granted a priority review by the FDA as a first-line treatment for patients with ALK-positive, metastatic NSCLC.
Keep an Eye on Novel Compound GPX-150 for Soft Tissue Sarcoma, Expert Says
The investigational compound 5-imino-13-deoxydoxorubicin showed promising activity in patients with metastatic and nonresectable soft tissue sarcoma.
Maintenance Lenalidomide Approved by the FDA for Myeloma
Lenalidomide has been approved by the FDA as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.
Inotuzumab Ozogamicin Granted FDA's Priority Review for ALL
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted a priority review designation by the FDA for the treatment of patients with relapsed or refractory ALL.
Gajewski Awarded Outstanding Investigator Award from NCI
Thomas Gajewski, MD, PhD, has been awarded an Outstanding Investigator Award by the National Cancer Institute.
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses a study of cobimetinib plus paclitaxel in triple-negative breast cancer (TNBC).
View More >


Nivolumab Approved by the FDA for Urothelial Carcinoma
Nivolumab Approved by the FDA for Urothelial Carcinoma
Nivolumab has been granted an accelerated approval by the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
Rucaparib Approved by FDA for Treatment of BRCA-Positive Ovarian Cancer
The FDA has approved rucaparib (Rubraca) as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.
Wierda Discusses Current Questions in Frontline CLL Treatment
William G. Wierda, MD, PhD, discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.
Blinatumomab Receives FDA Approval for Acute Lymphoblastic Leukemia
Blinatumomab (Blincyto) has received accelerated approval from the FDA for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
NDA for Neratinib in HER2-Positive Breast Cancer Accepted by FDA
A new drug application (NDA) for neratinib as an extended adjuvant therapy for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin) has been accepted by the FDA
FDA Gives Niraparib Fast Track Designation for Ovarian Cancer
Niraparib has been granted a fast track designation by the FDA as a treatment for women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer